These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 3086416

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Recombinant single-chain urokinase-type plasminogen activator during acute myocardial infarction.
    Diefenbach C, Erbel R, Pop T, Mathey D, Schofer J, Hamm C, Ostermann H, Schmitz-Hübner U, Bleifeld W, Meyer J.
    Am J Cardiol; 1988 May 01; 61(13):966-70. PubMed ID: 2452563
    [Abstract] [Full Text] [Related]

  • 4. Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.
    Ziskind AA, Gold HK, Yasuda T, Kanke M, Guerrero JL, Fallon JT, Saito T, Collen D.
    Circulation; 1989 Feb 01; 79(2):393-9. PubMed ID: 2492455
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Coronary thrombolysis with human single-chain, urokinase-type plasminogen activator (pro-urokinase) in patients with acute myocardial infarction.
    Van de Werf F, Nobuhara M, Collen D.
    Ann Intern Med; 1986 Mar 01; 104(3):345-8. PubMed ID: 3080936
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Thrombolysis with recombinant human single-chain urokinase-type plasminogen activator (rscu-PA): dose-response in dogs with coronary artery thrombosis.
    Van de Werf F, Jang IK, Collen D.
    J Cardiovasc Pharmacol; 1987 Jan 01; 9(1):91-3. PubMed ID: 2434801
    [Abstract] [Full Text] [Related]

  • 9. Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosis.
    Rapold HJ, Wu ZM, Stassen T, Van de Werf F, Collen D.
    Blood; 1990 Oct 15; 76(8):1558-63. PubMed ID: 2119830
    [Abstract] [Full Text] [Related]

  • 10. Enhancement of coronary thrombolysis with plasminogen pro-activator by pretreatment with heparin.
    Susawa T, Yui Y, Hattori R, Takatsu Y, Yui N, Takahashi M, Aoyama T, Murohara Y, Shirotani M, Kawai C.
    Jpn Circ J; 1988 Jan 15; 52(1):72-8. PubMed ID: 3129601
    [Abstract] [Full Text] [Related]

  • 11. Coronary thrombolysis with clot-selective plasminogen activators.
    Collen D, Bounameaux H.
    Herz; 1986 Feb 15; 11(1):9-15. PubMed ID: 3082731
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Coronary thrombolysis with recombinant human tissue-type plasminogen activator.
    Gold HK, Fallon JT, Yasuda T, Leinbach RC, Khaw BA, Newell JB, Guerrero JL, Vislosky FM, Hoyng CF, Grossbard E.
    Circulation; 1984 Oct 15; 70(4):700-7. PubMed ID: 6541103
    [Abstract] [Full Text] [Related]

  • 14. Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction.
    Van de Werf F, Vanhaecke J, de Geest H, Verstraete M, Collen D.
    Circulation; 1986 Nov 15; 74(5):1066-70. PubMed ID: 2429783
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Enhanced myocardial salvage by combined treatment with recombinant single-chain urokinase-type plasminogen activator and recombinant human superoxide dismutase in a canine coronary thrombosis model.
    Fincke U, Schneider J, Friderichs E, Giertz H, Flohé L.
    Arzneimittelforschung; 1988 Jan 15; 38(1):138-42. PubMed ID: 3365272
    [Abstract] [Full Text] [Related]

  • 17. Intravenous thrombolytic therapy with a combination of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator in acute myocardial infarction.
    Bode C, Schuler G, Nordt T, Schönermark S, Baumann H, Richardt G, Dietz R, Gurewich V, Kübler W.
    Circulation; 1990 Mar 15; 81(3):907-13. PubMed ID: 2106403
    [Abstract] [Full Text] [Related]

  • 18. Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology.
    Van de Werf F, Bergmann SR, Fox KA, de Geest H, Hoyng CF, Sobel BE, Collen D.
    Circulation; 1984 Mar 15; 69(3):605-10. PubMed ID: 6362907
    [Abstract] [Full Text] [Related]

  • 19. Clot-selective coronary thrombolysis with pro-urokinase.
    Loscalzo J, Wharton TP, Kirshenbaum JM, Levine HJ, Flaherty JT, Topol EJ, Ramaswamy K, Kosowsky BD, Salem DN, Ganz P.
    Circulation; 1989 Apr 15; 79(4):776-82. PubMed ID: 2494004
    [Abstract] [Full Text] [Related]

  • 20. Clot-selective coronary thrombolysis with low-dose synergistic combinations of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator. The Pro-Urokinase for Myocardial Infarction Study Group.
    Kirshenbaum JM, Bahr RD, Flaherty JT, Gurewich V, Levine HJ, Loscalzo J, Schumacher RR, Topol EJ, Wahr DW, Braunwald E.
    Am J Cardiol; 1991 Dec 15; 68(17):1564-9. PubMed ID: 1746455
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.